{"links":{"feed":"https://www.erudio.com/reports/panku-lung03-nct06500026/feed.json","html":"https://www.erudio.com/reports/panku-lung03-nct06500026","json":"https://www.erudio.com/reports/panku-lung03-nct06500026.json","markdown":"https://www.erudio.com/reports/panku-lung03-nct06500026.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"panku-lung03-nct06500026"}},"request":"https://www.erudio.com/contact?report=panku-lung03-nct06500026"},"offer":{"cited_clinicians":4,"cited_commentary_sources":5,"verified_hcp_statements":34,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":4},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"panku-lung03-nct06500026"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=panku-lung03-nct06500026","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/panku-lung03-nct06500026","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 34 verified statements · 12 from 4 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-19T09:02:33.325740Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":9,"no_commentary_found":1},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":4,"title":"Primary endpoint: Overall survival (OS)"},{"claim_count":6,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":4,"title":"Secondary endpoints"},{"claim_count":7,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":3,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":3,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":3,"title":"Safety and tolerability"},{"claim_count":0,"coverage":"no_commentary_found","id":"T6","registry_field":"designModule","source_count":0,"title":"Design and conduct"},{"claim_count":3,"coverage":"discussed","id":"A1","source_count":3,"title":"Dual-target rationale and exploratory receptor biomarkers"},{"claim_count":1,"coverage":"discussed","id":"A2","source_count":1,"title":"Platinum sensitivity and prior irinotecan"},{"claim_count":4,"coverage":"discussed","id":"A3","source_count":3,"title":"Phase III expectations drawn from earlier evidence"},{"claim_count":1,"coverage":"discussed","id":"A4","source_count":1,"title":"Broader ADC expectations for topotecan's role"}],"counts":{"beyond_population_findings":3,"beyond_population_statements":14,"cited_clinicians":4,"cited_clinicians_by_role":{"physician, Medical oncology":4},"cited_physicians":4,"cited_sources":6,"claims_by_expression_type":{"comparison":2,"interpretation":10,"opinion":7,"primary_context":3,"restatement":8,"uncertainty":3,"unspecified":1},"claims_by_kind":{"objective_result":2,"protocol_statement":1,"publication_statement":14,"source_observation":17},"clinician_statements":12,"evidence_units":19,"findings":5,"organisational_accounts":1,"people_cited":4,"people_identity_verified":4,"people_total":4,"screened_sources":13,"verified_claims":34},"findings_index":[{"cited_clinicians":2,"id":"F3","structure":{"claims":9,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":3,"views":3},"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":2,"passages":7,"sources":4,"sources_by_kind":{"commentary":3,"publication":1}},"title":"Iza-bren: why a clinician sees phase Ib response as a signal for phase III efficacy","title_holders":{"cited_claim_ids":["claim-679397e7a42e934c8625"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"9 statements from 2 speakers in 4 sources","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician"},{"cited_clinicians":2,"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":3,"views":5},"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":2,"passages":6,"sources":4,"sources_by_kind":{"commentary":3,"publication":1}},"title":"HER3 versus EGFR: what speakers say","evidence_line":"10 statements from 2 speakers in 4 sources"},{"cited_clinicians":2,"id":"F1","population":"beyond","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":4},"limitations":2,"links":{"context":0,"support":8},"ma_question":true,"named_voices":2,"passages":7,"sources":4,"sources_by_kind":{"commentary":3,"publication":1}},"title":"Phase Ib iza-bren: where clinicians split on the safety assessment","title_holders":{"cited_claim_ids":["claim-94039480efb9e5b8e1c4","claim-708c131e40ac77133c08"],"clinicians":true,"holders":2,"sides":[{"cited_claim_ids":["claim-94039480efb9e5b8e1c4"],"holders":1},{"cited_claim_ids":["claim-708c131e40ac77133c08"],"holders":1}],"speakers":2,"view":"split"},"evidence_line":"7 statements from 2 speakers in 4 sources","holder_line":"2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other; every named speaker in this finding is a confirmed clinician"},{"cited_clinicians":3,"id":"F2","population":"beyond","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":5,"views":5},"limitations":3,"links":{"context":1,"support":12},"ma_question":true,"named_voices":3,"passages":9,"sources":5,"sources_by_kind":{"commentary":4,"publication":1}},"title":"Phase I iza-bren: clinicians highlight ORR, but one flags fatal TRAEs","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-94039480efb9e5b8e1c4"],"clause":"one flags fatal TRAEs","holders":1},"cited_claim_ids":["claim-ec13750523071a51f613","claim-3806e1eccc080159c74b","claim-cf61719c78ca7e793157","claim-c8552665e9217a12fce6","claim-21efa3e3251cd7234253","claim-86f9f1ff28e6e31d3250"],"clinicians":true,"holders":3,"speakers":3,"view":"reading"},"evidence_line":"12 statements from 3 speakers in 5 sources","holder_line":"3 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one flags fatal TRAEs”"},{"cited_clinicians":1,"id":"F5","population":"beyond","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"limitations":1,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Other phase III ADC trials: why a clinician expects Topotecan to give way","title_holders":{"cited_claim_ids":["claim-6b843c31dda702d694de"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"1 statement from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"}],"open_question":{"basis":"From finding F3 (9 statements from 2 speakers in 4 sources)","cited_claim_ids":["claim-ad746f502a481acc9964","claim-94039480efb9e5b8e1c4","claim-679397e7a42e934c8625","claim-86f9f1ff28e6e31d3250","claim-f4b672b6ebe57a3159d7","claim-ded2c278daa367e7b7d0","claim-b2aab5a7b0f4d2a49a21","claim-927cc5cf58e181c42e26","claim-20e40598c37f5ab16767"],"finding_ids":["F3"],"question":"What do clinicians need PANKU-Lung03 to show about objective response, overall survival and fatal treatment-related toxicity before using izalontamab brengitecan rather than topotecan for recurrent SCLC after first-line platinum-based chemotherapy plus anti-PD-(L)1 therapy?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One X account sees response as suggesting phase III efficacy; an organizational account makes a numerical comparison with unnamed standards"},{"id":"section-2","level":2,"title":"One organizational X account reports an exploratory HER3–response association without an independent EGFR association"},{"id":"section-3","level":2,"title":"Beyond the trial population"},{"id":"section-4","level":3,"title":"One X account finds fatal toxicity concerning; another describes safety as manageable"},{"id":"section-5","level":3,"title":"Two X accounts see promise after first-line chemoimmunotherapy"},{"id":"section-6","level":3,"title":"One X author anticipates topotecan's displacement based on other ADC trials"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F3","shared_claims":1}],"id":"T1","label":"Primary endpoint: Overall survival (OS)"},{"findings":[{"id":"F3","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F3","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F3","shared_claims":3}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F3","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-19T09:02:33.325740Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-19T09:12:15Z","record_hash":"0c7be31d689d9e0080882632ac8f753d43d67fb2c17db5c0bedd454faf2b111b","release_hash":"be14be9482f2b50bff0a9c5ac413ae081cc74f9ce5335e143b94ddbc5a271418","report_id":"erudio-nct06500026","run_id":"ca37416f-4bda-4292-84db-0e85660019d0","schema_version":"5.0","slug":"panku-lung03-nct06500026","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A medical oncologist sees earlier iza-bren responses as suggesting benefit in PANKU-Lung03, but remains concerned about treatment-related deaths despite no observed ILD. Another medical oncologist emphasizes that hematologic toxicity was generally managed with supportive care. Direct trial commentary is limited: these safety assessments concern earlier iza-bren evidence, and the sources reviewed for this edition do not establish an advantage over topotecan.","examples":[],"meta_description":"13 sources screened · 34 verified statements (12 from clinicians verified by NPI or staff page) from 6 sources · 5 findings. Updated Nov 19, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-19T09:12:15Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":13},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","9 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 50 sources about other trials or topics are not included.","Discussion was identified mainly through the trial identifier and known drug names. Unnamed references, spelling variants and clinical-decision discussions about relapsed SCLC may therefore be missing.","The detailed efficacy and safety material concerns the supporting NCT05194982 phase Ib study. It must not be read as NCT06500026 results or as a head-to-head comparison with topotecan.","The reviewed accounts report different response estimates in 2025 and 2026 without explaining the differences. They do not establish why estimates differ or that any author changed their view.","No protocol text or exact regulatory label for BL-B01D1 was available in the sources reviewed. Detailed operational requirements and licensed-use implications cannot be established here.","Small subgroup analyses and exploratory biomarkers limit conclusions about treatment-history effects, receptor-based selection and mechanism."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":1,"registry":0,"regulatory":0,"x_thread":5,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":5,"results":1},"count":6,"evidence_window":{"end":"2026-09-13","start":"2025-05-30"},"retrieval_snapshot":"2026-11-19T08:01:46.866000Z","timeline":[{"count":2,"week":"2025-W22"},{"count":2,"week":"2026-W31"},{"count":1,"week":"2026-W37"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06500026:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06500026:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42497381","quote_policy":"no_derivatives"},{"id":"openfda:b6019088-cd94-43b4-b5ce-ba20b6b8021e:20260114","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1926251649867079951:ba7f430a-8fb5-46aa-b94a-924fbf5f159a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1926272536066601129:0d235da5-f9f6-4fe1-82eb-44d23007676b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1926278504565424328:321328bd-aee8-4ad2-9537-4a5295226377","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1926279046821749064:3a5b0164-78da-4622-9aba-cbc2960db3ec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1926279358408257580:5d40a69f-4100-412f-b1ef-5df3d1b55141","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928546651716587796:c13da9fd-e203-41fd-bbee-06c3ace771cf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928836909234635033:a55bb44c-fbfc-4061-817e-d93ef14e5a4a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045648205166121412:f9f0247d-7c5d-4d75-9375-7fc40c0f5373","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2081541351867392454:9d720050-fdde-4aa0-83fe-31449794ef65","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2083293906415001987:e713aa84-81e8-4b20-9751-003294dd2119","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098952287595212899:d7ffecbf-2de4-4446-80e9-70abfb06b27c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111487131717648633:6d4725b6-9572-4bbf-a8ee-eb9594360817","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114018695085478115:b0b3e0a7-6cb6-4d01-9e27-8572f5034096","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":13,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":13},"count":13,"evidence_window":{"end":"2026-10-24","start":"2025-05-24"},"retrieval_snapshot":"2026-11-19T08:01:46.866000Z","timeline":[{"count":5,"week":"2025-W21"},{"count":2,"week":"2025-W22"},{"count":1,"week":"2026-W16"},{"count":2,"week":"2026-W31"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W42"},{"count":1,"week":"2026-W43"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":17,"registry":0,"regulatory":0,"x_thread":17,"x_video":0,"youtube":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"izalontamab brengitecan","slug":"izalontamab-brengitecan"},{"brand_names":["Hycamtin"],"label":"topotecan","slug":"topotecan"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Small cell lung cancer","slug":"small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"PANKU-Lung03","aliases":["PANKU-Lung03","A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)","A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy"],"brief_title":"A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)","collaborators":["Baili-Bio (Chengdu) Pharmaceutical Co., Ltd."],"conditions":["Small Cell Lung Cancer"],"display_condition":"recurrent small cell lung cancer","display_interventions":[["izalontamab brengitecan (BL-B01D1)"]],"enrollment":{"count":722,"type":"ACTUAL"},"interventions":[{"name":"BL-B01D1","synonyms":["iza-bren","izalontamab brengitecan","BMS-986507"],"type":"DRUG"},{"name":"Topotecan","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06500026","official_title":"A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_endpoints":[{"description":"Overall survival (OS) is defined as the time between the subject's randomization date and subject's death.","measure":"Overall survival (OS)","timeFrame":"Up to approximately 24 months"}],"registered_date":{"date":"2024-07-15","type":"ACTUAL"},"registry_last_updated":"2026-04-17","registry_url":"https://clinicaltrials.gov/study/NCT06500026","short_name":"PANKU-Lung03","short_name_basis":"canonical_name","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","start_date":{"date":"2024-08-07","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"BL-B01D1-304","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}